AstraZeneca will soon start a phase 3 trial of a subcutaneous version of its anti-CD19 T-cell engager.
ApexOnco Front Page
Recent articles
A son of glembatumumab vedotin has just started its phase 1 study.
The company reveals its anti-GPRC5D T-cell engager.
The company admits defeat with zelenectide.
But this comes in second-line breast cancer, a use the group isn’t pursuing.
Ascentage hopes to become a new force in BTK.
Pivotal trials and novel combinations have started, but four programmes seem to have been discontinued.
Erda-iDRS maintains its promise in FGFR mutants, but adverse events could give pause.
